FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055583871> ?p ?o ?g. }

• W2055583871 endingPage "690" @default.
• W2055583871 startingPage "681" @default.
• W2055583871 abstract "Background:Tyrosine kinase inhibitors (TKIs) such as imatinib mesylate have revolutionized the treatment of primary unresectable and/or metastatic gastrointestinal stromal tumors (GISTs), providing durable disease control and extended survival. Although most patients eventually progress on therapy, dose escalation has been shown to benefit some patients. Sunitinib, a multitargeted kinase inhibitor is effective against imatinib-resistant or intolerant GIST patients. Although the cost of TKI therapy in GIST is high, no other effective systemic treatment options exist.Objective:Review pharmacoeconomic studies to determine the cost effectiveness (CE) of 1st- and 2nd-line TKI therapies in GIST.Methods:A literature review using Medline and PubMed databases was conducted to identify published economic analyses of TKI therapy in GIST. Key results from these studies were analyzed.Results:Six pharmacoeconomic studies were identified, including three analyses of 1st-line imatinib and three analyses of 2nd-line sunitinib. These studies employed various time horizons and discount rates and modeled CE from a number of different perspectives. Most of the pharmacoeconomic studies reviewed used survival as their efficacy endpoint, projecting outcomes beyond available data to model CE. Analyses of 2nd-line sunitinib using survival additionally faced the challenge of adjusting for the effect of placebo crossover to active treatment in the pivotal phase III study. Most studies used Markov techniques with a range of transition probabilities.Conclusions:Published pharmacoeconomic studies of 1st- and 2nd-line TKI therapy for advanced GIST employ various time horizons, discount rates, and different CE models. Consequently, these differences make comparisons between studies difficult. Studies of 1st-line imatinib concluded that imatinib was cost effective in advanced, metastatic GIST. Likewise, based on data reviewed here, 2nd-line sunitinib appears to be cost effective in patients with advanced GIST who are intolerant/resistant to imatinib. Key limitations of this review included inconsistency among the studies evaluated with regard to methodologies, countries of origination (currency and healthcare systems), and patient demographics." @default.
• W2055583871 created "2016-06-24" @default.
• W2055583871 creator A5021788583 @default.
• W2055583871 creator A5037149615 @default.
• W2055583871 date "2010-11-10" @default.
• W2055583871 modified "2023-10-16" @default.
• W2055583871 title "Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors" @default.
• W2055583871 cites W1516279414 @default.
• W2055583871 cites W1626699548 @default.
• W2055583871 cites W1861968676 @default.
• W2055583871 cites W1980482008 @default.
• W2055583871 cites W1981491302 @default.
• W2055583871 cites W1992447918 @default.
• W2055583871 cites W1992878563 @default.
• W2055583871 cites W2004599980 @default.
• W2055583871 cites W2010415450 @default.
• W2055583871 cites W2011324997 @default.
• W2055583871 cites W2015015957 @default.
• W2055583871 cites W2023549507 @default.
• W2055583871 cites W2025447556 @default.
• W2055583871 cites W2048030685 @default.
• W2055583871 cites W2055070782 @default.
• W2055583871 cites W2061345986 @default.
• W2055583871 cites W2068079378 @default.
• W2055583871 cites W2071056007 @default.
• W2055583871 cites W2072098827 @default.
• W2055583871 cites W2101986793 @default.
• W2055583871 cites W2109361235 @default.
• W2055583871 cites W2110509198 @default.
• W2055583871 cites W2113144077 @default.
• W2055583871 cites W2115504770 @default.
• W2055583871 cites W2117624277 @default.
• W2055583871 cites W2119505091 @default.
• W2055583871 cites W2122159057 @default.
• W2055583871 cites W2124196948 @default.
• W2055583871 cites W2125317841 @default.
• W2055583871 cites W2129093214 @default.
• W2055583871 cites W2139511378 @default.
• W2055583871 cites W2140626630 @default.
• W2055583871 cites W2142990859 @default.
• W2055583871 cites W2151289323 @default.
• W2055583871 cites W2156669735 @default.
• W2055583871 cites W2169363650 @default.
• W2055583871 cites W2171620774 @default.
• W2055583871 cites W2211998466 @default.
• W2055583871 cites W2243379994 @default.
• W2055583871 cites W2273177921 @default.
• W2055583871 cites W2276801579 @default.
• W2055583871 cites W2314511842 @default.
• W2055583871 cites W2324850882 @default.
• W2055583871 cites W2487815795 @default.
• W2055583871 doi "https://doi.org/10.3111/13696998.2010.534670" @default.
• W2055583871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21067355" @default.
• W2055583871 hasPublicationYear "2010" @default.
• W2055583871 type Work @default.
• W2055583871 sameAs 2055583871 @default.
• W2055583871 citedByCount "8" @default.
• W2055583871 countsByYear W20555838712012 @default.
• W2055583871 countsByYear W20555838712013 @default.
• W2055583871 countsByYear W20555838712014 @default.
• W2055583871 countsByYear W20555838712016 @default.
• W2055583871 countsByYear W20555838712018 @default.
• W2055583871 crossrefType "journal-article" @default.
• W2055583871 hasAuthorship W2055583871A5021788583 @default.
• W2055583871 hasAuthorship W2055583871A5037149615 @default.
• W2055583871 hasBestOaLocation W20555838711 @default.
• W2055583871 hasConcept C121608353 @default.
• W2055583871 hasConcept C126322002 @default.
• W2055583871 hasConcept C143998085 @default.
• W2055583871 hasConcept C16930146 @default.
• W2055583871 hasConcept C2775922572 @default.
• W2055583871 hasConcept C2777583451 @default.
• W2055583871 hasConcept C2778729363 @default.
• W2055583871 hasConcept C2778820342 @default.
• W2055583871 hasConcept C2779490328 @default.
• W2055583871 hasConcept C3019892230 @default.
• W2055583871 hasConcept C71924100 @default.
• W2055583871 hasConceptScore W2055583871C121608353 @default.
• W2055583871 hasConceptScore W2055583871C126322002 @default.
• W2055583871 hasConceptScore W2055583871C143998085 @default.
• W2055583871 hasConceptScore W2055583871C16930146 @default.
• W2055583871 hasConceptScore W2055583871C2775922572 @default.
• W2055583871 hasConceptScore W2055583871C2777583451 @default.
• W2055583871 hasConceptScore W2055583871C2778729363 @default.
• W2055583871 hasConceptScore W2055583871C2778820342 @default.
• W2055583871 hasConceptScore W2055583871C2779490328 @default.
• W2055583871 hasConceptScore W2055583871C3019892230 @default.
• W2055583871 hasConceptScore W2055583871C71924100 @default.
• W2055583871 hasIssue "4" @default.
• W2055583871 hasLocation W20555838711 @default.
• W2055583871 hasLocation W20555838712 @default.
• W2055583871 hasOpenAccess W2055583871 @default.
• W2055583871 hasPrimaryLocation W20555838711 @default.
• W2055583871 hasRelatedWork W1559702962 @default.
• W2055583871 hasRelatedWork W1939360645 @default.
• W2055583871 hasRelatedWork W1973125946 @default.
• W2055583871 hasRelatedWork W2006171747 @default.
• W2055583871 hasRelatedWork W2067256453 @default.

• next